Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Big Pharma friend argenx has snapped up an FDA priority review voucher from Bayer for $98 million.

The little biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug and get it approved more quickly, for its late-stage drug efgartigimod—but not in the indication you might think.